摘要
乳腺癌作为全球女性最常见的恶性肿瘤,其发病率呈逐年上升趋势,对女性健康构成了严重威胁。传统的乳腺癌治疗手段仍存在诸多局限性,抗体药物偶联物(antibody-drug conjugate,ADC)是一类治疗乳腺癌的新型靶向药物,在人表皮生长因子受体2(human epidermal growth factor receptor-2,HER2)阳性乳腺癌治疗中疗效显著,同时在晚期三阴性乳腺癌和部分HER2低表达的乳腺癌治疗中也取得重要进展,为不同乳腺癌分子分型的人群提供更多选择。本文主要针对乳腺癌ADC类药物治疗的最新进展及未来发展方向进行阐述与讨论。
Breast cancer,as the most common malignant tumors among women globally,has seen an increasing incidence rate year by year,posing a serious threat to women's health.Traditional treatment methods for breast cancer still have many limitations.Antibody-drug conjugates(ADCs)are a new type of targeted drugs for treating breast cancer,which have shown remarkable efficacy in the treatment of HER2-positive breast cancer.At the same time,important progress has also been made in the treatment of advanced triple-negative breast cancer(TNBC)and some breast cancers with low HER2 expression,providing more options for people with different molecular subtypes of breast cancer.This article mainly elaborates and discusses the latest progress after the treatment with ADC drugs for breast cancer and the future development directions.
作者
张扬
张鑫然
敖东旭
蔡君
Zhang Yang;Zhang Xinran;Ao Dongxu;Cai Jun(Oncology Department of The First Affiliated Hospital of Yangtze University,Hubei Jingzhou 434000,China)
出处
《临床普外科电子杂志》
2025年第3期65-70,109,共7页
Journal of General Surgery for Clinicians(Electronic Version)
关键词
抗体药物偶联物
乳腺癌
研究进展
Antibody-drug conjugates drugs
Breast cancer
Research progress
